The 2026 GLP-1 landscape — every drug, every generation.
In ten years, obesity pharmacology has gone from "a few percentage points of weight loss" to "the most effective metabolic intervention ever made available." Here is the complete map — what is approved, what is filed, what is in trials, and how to think about which generation you are using.
Four generations of incretin therapy.
The simplest way to keep this field straight is by generation — defined by how many receptors a single molecule activates. Each new generation has produced more weight loss than the last:
- Generation 1: Single agonist (GLP-1). Semaglutide. ~14.9% mean weight loss in Phase 3.
- Generation 2: Dual agonist (GLP-1 + GIP). Tirzepatide. ~22.5% mean weight loss in Phase 3.
- Generation 3: Triple agonist (GLP-1 + GIP + glucagon). Retatrutide. ~28.7% mean weight loss in Phase 3 (TRIUMPH-4, December 2025).
- Generation 4: Combination and oral. CagriSema (semaglutide + cagrilintide amylin agonist), orforglipron (oral non-peptide GLP-1). Different mechanisms, different reasons to exist.
Semaglutide — the foundation.
Semaglutide
Ozempic (T2D), Wegovy (obesity; a weekly injection and, since December 2025, a daily pill), Rybelsus (oral, T2D). Same molecule, different brand names and indications. The drug that made GLP-1 a household word. Phase 3 STEP program produced ~14.9% mean weight loss at 68 weeks. The SELECT trial (2023) demonstrated a 20% reduction in major adverse cardiovascular events in patients with established cardiovascular disease and no diabetes — a uniquely strong evidence base that no other GLP-1 has yet matched in that group.
Where semaglutide still wins in 2026: cardiovascular protection, oral formulation availability (Rybelsus and the Wegovy pill), and lower cost in some payer scenarios. Where it loses: weight-loss efficacy versus tirzepatide.
Tirzepatide — the current standard.
Tirzepatide
Mounjaro (T2D), Zepbound (obesity, OSA). Adding the GIP receptor delivered ~22.5% mean weight loss in SURMOUNT-1 — and SURMOUNT-5 (NEJM 2025) confirmed superiority versus semaglutide head-to-head (20.2% vs. 13.7%). Tirzepatide also has the cleaner GI tolerability profile because GIP agonism modulates the nausea pathway.
In 2024, tirzepatide was added to the FDA's approved indication list for obstructive sleep apnea in adults with obesity — the first GLP-1/GIP to reach that indication. In August 2026, on the strength of the SURPASS-CVOT trial, the FDA also approved Mounjaro to reduce the risk of cardiovascular death, heart attack, and stroke in adults with type 2 diabetes at high cardiovascular risk.
Retatrutide — the headline drug.
Retatrutide (LY3437943)
The first triple agonist to reach Phase 3. TRIUMPH-4 (December 2025) produced 28.7% mean weight loss at the 12 mg dose over 68 weeks — the highest figure reported in a Phase 3 obesity trial at the time. Adding the glucagon receptor turns up resting energy expenditure and lipolysis, which is what allows the additional weight loss.
TRIUMPH-1 (the largest registration trial) reported in May 2026, and TRIUMPH-2 and TRIUMPH-3 in July; the cardiovascular outcomes trial runs into 2029. Eli Lilly plans to file with the FDA in the first quarter of 2027, which puts a decision in late 2027 or early 2028. Retatrutide is investigational as of October 2026 and is not legally compoundable in the U.S.
For the deep dive, read our Retatrutide 2026 article covering the Phase 3 program, mechanism, and FDA timeline.
The diversifying frontier.
Generation 4 is less about adding receptors and more about (a) different mechanisms, (b) different delivery formats, and (c) the maturation of the field beyond "more weight loss is always better."
CagriSema
Novo Nordisk's combination of semaglutide and cagrilintide (a long-acting amylin analog). Filed for FDA approval in December 2025; the FDA had not announced a decision as of early October 2026. Phase 3 REDEFINE results showed weight loss between semaglutide alone and tirzepatide alone, with potentially smoother appetite suppression because amylin and GLP-1 hit different satiety pathways.
Orforglipron
Eli Lilly's oral, non-peptide GLP-1. ATTAIN-1 (completed August 2025) showed 12.4% mean weight loss at 72 weeks. Significantly less weight loss than injectable competitors, but the format advantage is real: orforglipron is an oral pill that does not require the food/water timing restrictions that Rybelsus does. The FDA approved it for weight management in April 2026 as Foundayo.
For patients who would rather not inject, it is one of two GLP-1 pills now approved for weight management, alongside the Wegovy pill.
Survodutide
Boehringer Ingelheim's GLP-1/glucagon dual agonist (notably without GIP). Phase 2 produced ~19% weight loss; in Phase 3, SYNCHRONIZE-1 (April 2026) reported up to 16.6% at 76 weeks. The mechanistic interest is high because survodutide is studying whether you can replicate retatrutide-class weight loss without GIP — relevant if any GIP-related safety signal emerges in the broader class.
The full landscape, side-by-side.
| Drug | Mechanism | Phase 3 weight loss | FDA status |
|---|---|---|---|
| Semaglutide | GLP-1 | ~14.9% | Approved |
| Tirzepatide | GLP-1 + GIP | ~22.5% | Approved |
| CagriSema | GLP-1 + amylin | ~22.7% | Filed · decision pending |
| Survodutide | GLP-1 + glucagon | Up to 16.6% (SYNCHRONIZE-1) | Investigational |
| Orforglipron | Oral GLP-1 (non-peptide) | ~12.4% | Approved Apr 2026 (Foundayo) |
| Retatrutide | GLP-1 + GIP + glucagon | ~28.7% | Phase 3 reported · filing planned Q1 2027 |
Phase 3 figures are mean values from largest published trials; cross-trial comparisons should be interpreted with caution because populations and durations differ.
What this means for you.
- If you are starting in 2026: tirzepatide is the highest-efficacy approved option. Semaglutide is the choice when CV protection is the priority. Both are accessible, well-studied, and supported by branded supply chains.
- If you cannot inject: two GLP-1 pills are now approved for weight management — the Wegovy pill (oral semaglutide, December 2025) and Foundayo (orforglipron, April 2026). Foundayo has no food or water timing rules; the semaglutide pills do.
- If you are already on tirzepatide and stable: the right move in 2026 is rarely to switch. Optimize the rest of the picture (sleep, training, hormones, body composition) before adding more drug or switching molecules.
- If you are aiming for >25% weight loss: retatrutide is the drug to watch. Until launch, tirzepatide at maximum tolerated dose paired with a serious lifestyle and resistance-training architecture is the closest substitute.
- If you are CV-disease-stable: stay on semaglutide unless your physician has a specific reason to switch. Its MACE benefit in people without diabetes (the SELECT trial) is unique so far; tirzepatide's cardiovascular indication (August 2026) covers adults with type 2 diabetes at high cardiovascular risk.
The 2026 landscape, asked and answered.
- Is more weight loss always better?
- No. Beyond a certain point, additional pharmacologic weight loss costs lean mass — which costs longevity. The frontier of this field is now learning to titrate to a target loss and maintain, rather than maximize loss. This is why the TRIUMPH program is studying a 4 mg maintenance dose alongside the 9 mg and 12 mg induction doses.
- Will compounded versions return?
- Almost certainly not for semaglutide and tirzepatide while they remain in adequate supply. Compounded versions only become legal when a drug is on FDA shortage lists. As of October 2026, neither is. Compounded "research-grade" versions sold online are not legal medical products and we do not prescribe from those sources.
- What about microdosing GLP-1s?
- "Microdosing" of GLP-1s is unstudied at the dose ranges patients use it. There is no Phase 3 evidence that doses below the FDA-approved schedule produce durable benefit. We do not microdose unprovably; we may dose conservatively when tolerability requires.
- Will retatrutide actually work in real patients the way TRIUMPH-4 showed?
- Real-world response is consistently lower than trial response — this is true for every drug, not just GLP-1s. Expect retatrutide real-world weight loss to be in the 22–25% range on average, which is still higher than tirzepatide.
- How long do you stay on a GLP-1?
- Indefinite, in most cases — or with a structured taper-and-maintenance plan. Within 12 months of stopping, two-thirds of weight is typically regained without aggressive lifestyle architecture. We treat these drugs as ongoing therapy, like statins or thyroid replacement, for most patients.
Continue the weight-loss series.
The right drug for you depends on more than the headline.
Labs, history, comorbidities, payer access, and goals all factor in. We map your decision against the full landscape — not whichever drug the loudest voice on the internet recommends.
Request a consultation